Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of April 2026, with a report date of April 27, 2026. The filing details a private placement of securities and a warrant inducement transaction designed to raise capital for the company's CDMO platform expansion, customer program advancement, and immunotherapy pipeline investment.
Key Financial Metrics
- Gross Proceeds: Approximately $2.61 million from the combined Private Placement and Warrant Inducement transactions.
- Offering Price: $0.48 per American Depositary Share (ADS) or Pre-Funded Warrant.
- Shares Issued: 5,208,333 Offering ADSs (each representing 4,000 ordinary shares).
- Transaction Fees: A cash fee of 7.0% of gross proceeds plus up to $70,000 in reimbursable expenses paid to the financial advisor (A.G.P./Alliance Global Partners).
- Additional Compensation: Issuance of warrants to the financial advisor to acquire up to 260,417 ADSs at an exercise price of $0.53.
- Liquidity and Debt: The filing does not provide specific values for total cash on hand, total debt, or operating cash flow prior to this transaction.
Material Changes
The primary material change is the capital raise executed on April 23, 2026, with closing expected on April 27, 2026. This includes:
- Private Placement: Sale of 5,208,333 ADSs/Pre-Funded Warrants and the issuance of Series A Warrants (2-year term, $0.48 exercise price) and Series B Warrants (5-year term, $0.55 exercise price).
- Warrant Inducement: An agreement to allow an investor to exercise January 2024 Warrants at a reduced price of $0.48 (down from $6.50) in exchange for issuing new Inducement Warrants for up to 458,621 ADSs at $0.55.
- Ownership Caps: Beneficial ownership limitations of 4.99% (or 9.99% upon election) apply to warrant exercises.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: Management intends to use net proceeds alongside existing cash resources to expand the CDMO platform, advance customer programs, and selectively invest in the immunotherapy pipeline. The financing is viewed as supportive of the company's growth strategy.
Restrictions and Risks:
- Lock-up Periods: The Company is restricted from issuing new ADSs or equivalents for 30 days following the registration statement effective date. A 90-day prohibition on "Variable Rate Transactions" also applies.
- Registration Rights: The Company must file a registration statement for resale of the securities within 15 days of April 23, 2026, and use commercially reasonable efforts to make it effective within 60 to 90 days.
- Unregistered Securities: The Inducement Warrants and underlying ADSs are unregistered and issued under Section 4(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $2.61 million gross proceeds receipt.
- Review the filed Registration Statement (Exhibit 10.2) to confirm the timeline for the resale registration effectiveness.
- Assess the dilution impact of the 5,208,333 new ADSs and the aggregate warrants issued (Series A, Series B, Inducement, and Financial Advisor warrants).
- Confirm the specific terms of the "Variable Rate Transaction" prohibition to understand future financing flexibility.
- Examine the company's existing cash resources to determine the runway provided by the net proceeds after the 7% fee and expenses.